We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [–81.1 mU/ml mean difference; 95% confidence intervals (95% CI): –30.3; –131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01–0.38, P=0.002] than those starting a lamivudine sparing-regimen.
References
1.
PuotiM., AiroldiM., BrunoR., ZaniniB., SpinettiA., & PezzoliC.Hepatitis B virus co-infection in human immunodeficiency virus infected subjects.AIDS Review2002; 4: 28–36.
2.
ThioC.L., SeabergE.C., SkolaskiR., PhairJ., VisscherB., MunozA., & ThomasD.L.HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter Cohort Study (MACS).Lancet2002; 360: 1921–1926.
3.
DoreG.J., CooperD.A., BarrettC., GohL.E., ThakrarB., & AtkinsM.Dual efficacy of lamivudine treatment in human immunodeficiency virus hepatitis B co-infected persons in a randomised, controlled study (CAESAR).Journal of Infectious Diseases1999; 180: 607–613.
4.
NelsonM., PortsmouthS., StebbingJ., AtkinsM., BarrA., MatthewsG., PillayD., FisherM., BowerM., & GazzardB.An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals.AIDS2003; 17: F7–F10.
5.
BenhamouY., BochetM., ThibaultV., Di MartinoV., CaumesE., BricaireF., OpolonP., KatlamaC., & PoynardT.Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.Hepatology1999; 30: 1302–1306.
6.
PillayD., CaneP.A., RatcliffeD., AtkinsM., & CooperD.Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.AIDS2000; 14: 1111–1116.
7.
BessesenM., IvesD., CondreayL., LawrenceS., & ShermanK.E.Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.Clinical Infectious Diseases1999; 28: 1032–1035.
8.
BrunoR., SacchiP., MalfitanoA., & FiliceG.YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient.Gastroenterology2001; 121: 1027–1028.
9.
BonaciniM., KurzA., LocarniniS., AyresA., & GibbsC.Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.Gastroenterology2002; 122: 244–245.
10.
WitF.W., WeverlingG.J., WeelJ., JurriaansS., & LangeJ.M.Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.Journal of Infectious Diseases2002; 186: 23–31.
11.
d'Arminio MonforteA., Cozzi LepriA., RezzaG., PezzettiP., AntinoriA., PhillipsA.N., AngaranoG., ColangeliV., De LucaA., IppolitoG., CaggeseL., SosciaF., FiliceG., GrittiF., NarcisoP., TirelliU., & MoroniM. for the I.CO.N.A. Study Group. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen and its determinants in a clinical cohort of antiretroviral naïve patientsAIDS2000; 14: 499–507.
12.
CooleyL., AyresA., BartholomeuszA., LewinS., CroweS., MijchA., LocarniniS., & SasadeuszJ.Prevalence and characterization of lamivudine resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.AIDS2003; 17: 1649–1657.
13.
NunezM., Perez-OlmedaM., DiazB., RiosP., Gonzalez-LahozJ., & SorianoV.Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.AIDS2002; 16: 2352–2354.
14.
GaetaG.B., StornaiuoloG., PreconeD.F., LobelloS., ChiaramonteM., StroffoliniT., ColucciG., & RizzettoM.Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study.Journal of Hepatology2003; 39: 1036–1041.
